Effects of Diabetes Mellitus on the Disposition of Tofacitinib, a Janus Kinase Inhibitor, in Rats

Tofacitinib, a Janus kinase inhibitor, was developed for the treatment of rheumatoid arthritis. Recently, it has been associated with an increased change in arthritis development in patients with diabetes. Herein, we evaluated the pharmacokinetics of tofacitinib after intravenous (10 mg/kg) and oral...

Descripción completa

Detalles Bibliográficos
Autores principales: Gwak, Eun Hye, Yoo, Hee Young, Kim, So Hee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Society of Applied Pharmacology 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327145/
https://www.ncbi.nlm.nih.gov/pubmed/32209733
http://dx.doi.org/10.4062/biomolther.2020.006

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7327145/
https://www.ncbi.nlm.nih.gov/pubmed/32209733
http://dx.doi.org/10.4062/biomolther.2020.006

Ejemplares similares